AbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.

The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy.

Telix and Regeneron have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies.

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the commercialisation of bofanglutide injection in South Korea.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

RoosterBio has partnered with MineBio Life Sciences to expand access to scalable, research-grade and cGMP-grade MSC solutions across China.

Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.

Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn).

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HCRx to support the planned launch of AD109.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.